SDZ.SW
SDZ.SW
CH1243598427
SANDOZ GROUP N
Loading chart...

Company Profile

Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. to broaden patient access to biosimilar medicines. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.

Related stocks

GALD.SW
GALD.SW • Switzerland
GALDERMA GROUP N
164.95 CHF
46.34B USD 1Y +12.1%
HLN.L
HLN.L • United Kingdom
HALEON PLC ORD GBP0.01
349.2 GBp
40.64B USD 1Y +1%
SOBI.ST
SOBI.ST • Sweden
Swedish Orphan Biovitrum AB
428.4 SEK
14.92B USD 1Y +35.3%
MRK.DE
MRK.DE • Germany
MERCK KGAA I
137.85 EUR
67.16B USD 1Y +13%
IPN.PA
IPN.PA • France
IPSEN
142.7 EUR
13.18B USD 1Y +20.7%
SFZN.SW
SFZN.SW • Switzerland
SIEGFRIED N
67.5 CHF
3.56B USD 1Y -18.7%
ALKS
ALKS • Ireland
Alkermes plc
40.61 USD
6.81B USD 1Y +27.3%
HLUN-B.CO
HLUN-B.CO • Denmark
H. Lundbeck A/S B
45.96 DKK
6.83B USD 1Y +0.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
3Y Volatility
30.0% p.a.
Max Drawdown (3Y)
-32.1%
Sharpe Ratio (3Y)
1.28
Beta Factor
0.46
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 59.6 (Elevated multiple compression risk)
ende